Navigation Links
Drug Effective for Temporary Sleep Disruptions
Date:12/2/2008

Trials of tasimelteon show it could aid shift workers, people affected by jet leg

TUESDAY, Dec. 2 (HealthDay News) -- The experimental drug tasimelteon helps treat temporary insomnia caused by jet lag or night shifts, according to the results of two new clinical trials.

The phase II study included 39 people randomly assigned to receive either 10 milligrams, 20 mg, 50 mg or 100 mg of tasimelteon, or a placebo. They were monitored for seven nights -- three at baseline, three after a five-hour advance of sleep-wake schedule with treatment before sleep, and one night after treatment.

The phase III trial included 411 people who had transient insomnia induced in a sleep clinic by a five-hour advance of their sleep-wake cycle. They received either 20 mg, 50 mg, or 100 mg of tasimelteon, or a placebo, 30 minutes before bedtime.

The patients in the trials were monitored to determine their sleep efficiency (amount of actual sleep during their time in bed) and sleep latency (time it took them to fall asleep). Compared to placebo, tasimelteon (a melatonin analogue) improved sleep efficiency and reduced sleep latency, according to the researchers. They also found that patients taking tasimelteon showed an earlier shift in plasma melatonin rhythm.

The findings were published online and in an upcoming print issue of the The Lancet.

"The development of melatonin analogues, which specifically target melatonin receptors, will also help us to understand more about the role of the hormone melatonin in the regulation of sleep," the American and Australian researchers said in a journal news release.

"By simultaneously improving sleep latency and sleep maintenance with a shift in circadian rhythms, tasimelteon has the potential for the treatment of patients with transient insomnia associated with circadian rhythm sleep disorders, including people affected by jet leg, or those who work at night, and early-riser workers," the study authors concluded.

More information

The U.S. National Sleep Foundation has more about shift work.



-- Robert Preidt



SOURCE: The Lancet, news release, Dec. 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
4. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
7. Case Management Cost-Effective Way to Cut Heart Risks
8. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
9. Nasal Anthrax Vaccine Proves Effective in Animal Study
10. Family-based treatment more effective than supportive psychotherapy in treating bulimia
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Effective  for Temporary Sleep Disruptions
(Date:5/25/2016)... ... May 25, 2016 , ... ... has seen a significant spike in their clients' employee participation for their wellness ... health screening by implementing a high-deductible health plan with outcome-based deductible incentives. As ...
(Date:5/25/2016)... ... , ... Stern Environmental Group , of Secaucus, New Jersey, working in ... Stern’s Real Time Monitoring (RTM) Device. Stern Environmental Group will sell the first ... for use in dormitories, shelters, and nursing homes for real time bedbug monitoring in ...
(Date:5/24/2016)... Milwaukee, WI (PRWEB) , ... May 24, 2016 ... ... has announced that Rudolfo (Rudy) Cifolelli has joined the company as Vice President ... and the development of U.S. and international sales in the rapidly expanding field ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and Communications ... the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and ...
(Date:5/24/2016)... ... 24, 2016 , ... How to Write Error Free Procedures, **Presented by Ginette ... Human error is known to be the major cause of quality and production losses ... eliminated, many human performance problems can be prevented. , How to Write Error Free ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... Non-invasive diagnostic test realizes the potential of ... be presented at Yissum’s booth, at IATI-BIOMED 2016 conference  ... the Hebrew University of Jerusalem announced today it ... MKI, the technology investment arm of Morris Kahn , ... early detection of multiple diseases by analyzing circulating DNA ...
(Date:5/23/2016)... May 23, 2016 Gamida Cell, ... treatment of cancer and orphan genetic diseases, announced today ... $4.4 million from the Israel Innovation Authority (formerly the ... of Economy and Industry. The mission of the Israel ... various industries, including science and technology, while stimulating economic ...
(Date:5/23/2016)... Conn. , May 23, 2016   ... has entered into an agreement with Egalet Corporation ... patent claims. As part of the agreement the ... and will enable all three companies to develop ... properties. "This agreement reflects the commitment ...
Breaking Medicine Technology: